+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drug Formulation Market - Global Forecast 2025-2030- Product Image
Drug Formulation Market - Global Forecast 2025-2030- Product Image
Sale

Drug Formulation Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967541
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drug Formulation Market grew from USD 2.55 trillion in 2024 to USD 2.70 trillion in 2025. It is expected to continue growing at a CAGR of 5.76%, reaching USD 3.57 trillion by 2030.

Navigating the Evolving Terrain of Drug Formulation Research through Strategic Insights on Innovation Pathways and Market Dynamics

In today’s pharmaceutical landscape, the quest for innovative drug formulation solutions has never been more critical. Advances in active pharmaceutical ingredients demand equally sophisticated delivery systems, while shifting regulatory frameworks continue to challenge developers. Against this backdrop, industry stakeholders seek clarity on drivers such as formulation stability, patient adherence, and manufacturing efficiency. Moreover, the convergence of precision medicine and biological therapies is reshaping conventional approaches, prompting companies to rethink the very foundations of how drugs are designed, tested, and commercialized.

As a result, this executive summary offers a comprehensive overview of the transformative forces at work. It synthesizes the latest breakthroughs in formulation platforms, contextualizes emerging regulatory expectations, and highlights the competitive dynamics influencing R&D priorities. By unpacking these core elements, decision-makers can navigate uncertainty with greater confidence, ensuring that pipeline strategies align with market realities and stakeholder needs.

Uncovering Fundamental Transformative Shifts That Are Redefining Drug Formulation Development Across Innovation, Regulation, and Patient-Centric Care

The drug formulation landscape is experiencing a profound metamorphosis driven by scientific breakthroughs and strategic realignments. First, the rise of biologics and cell-based therapies has elevated the importance of delivery systems capable of preserving molecular integrity, thus accelerating investment in liposomal and nanoparticle technologies. Simultaneously, regulatory agencies worldwide are adopting harmonized guidelines for complex formulations, promoting greater clarity while raising the bar on clinical validation requirements.

Furthermore, patient-centric considerations are reshaping dosing paradigms, with greater emphasis on transdermal patches, inhalation devices, and oral thin films that enhance adherence and therapeutic outcomes. As these trends converge, traditional modalities like creams and ointments are being reimagined through controlled-release chemistries, while injectables continue to evolve with innovative subcutaneous and intramuscular delivery platforms. In this transformed environment, manufacturing agility and cross-functional collaboration have become essential differentiators for organizations tasked with bringing next-generation therapies to market.

Analyzing the Far-Reaching Cumulative Effects of United States Trade Tariffs in 2025 on Global Drug Formulation Supply Chains and Manufacturing Costs

The imposition of revised trade tariffs in the United States during 2025 has sent ripples throughout global drug formulation supply chains. Manufacturers reliant on imported excipients and advanced delivery components are now navigating cost fluctuations that impact formulation budgets and production timelines. In parallel, firms with in-country production capabilities have recalibrated procurement strategies to mitigate exposure, leading to strategic partnerships with domestic suppliers and vertical integration initiatives.

Despite short-term challenges, tariff adjustments are driving a renewed focus on supply chain resilience. Companies are diversifying raw material sourcing, investing in backward compatibility of manufacturing lines, and exploring alternative excipient chemistries less vulnerable to cross-border levies. Consequently, these adaptations are fostering long-term efficiencies, encouraging a shift toward localized production hubs, and reinforcing the strategic importance of adaptive risk management within formulation planning.

Deriving Strategic Segmentation Insights Spanning Therapeutic Areas through Delivery Technologies to Drive Targeted Formulation Strategies

An integrated segmentation framework reveals critical insights into how diverse therapeutic categories, formulation formats, and delivery routes intersect to shape development priorities. In anti-infectives, the push for targeted release in solid tablets and granules echoes broader efforts to optimize systemic exposure, while in cardiovascular applications, discrete solutions and suspensions address rapid onset requirements for arrhythmia, dyslipidemia, and hypertension therapies. Elsewhere, central nervous system candidates for Alzheimer’s, depression, and Parkinson’s are increasingly formulated as transdermal gels and patches to overcome blood-brain barrier challenges.

Meanwhile, applications in oncology, spanning breast, colorectal, and lung indications, combine injectable subcutaneous monoclonal antibodies with nanocarrier-based controlled-release systems to enhance tumor targeting. Gastrointestinal and respiratory markets have responded to patient preferences by blending oral powders, capsules, and metered dose inhalers. Across distribution networks-from clinics and drug stores to online pharmacies-small molecule and peptide-based products maintain prominence, even as vaccine formulation and targeted delivery platforms gain traction. Finally, veterinary applications adopt many of the same formulation innovations as human health, underscoring the cross-sector synergies that drive shared technology adoption.

Examining Key Regional Insights Across the Americas, Europe, Middle East & Africa, and Asia-Pacific to Illuminate Diverse Drivers of Drug Formulation Growth

Regional dynamics underscore the multifaceted nature of drug formulation growth. In the Americas, strong investment in biologics and vaccine formulation is fueling expansion of controlled-release injectables and liposomal platforms, particularly in major hubs such as the United States and Canada. Shifting regulatory frameworks in Latin American markets are also encouraging local manufacturing, with an emphasis on oral solid dosage forms that can meet rising patient volumes.

Over in Europe, Middle East & Africa, collaborative consortiums are advancing nanoparticle and targeted delivery research while addressing supply volatility through harmonized excipient standards. Regulatory convergence across the European Union has positioned the region as a strategic testbed for innovative transdermal and nasal spray formulations. Meanwhile, emerging markets in the Middle East and Africa are beginning to adopt semisolid creams and ointments to tackle growing chronic disease burdens.

In Asia-Pacific, the rapid scaling of pharmaceutical manufacturing capacity has been complemented by a surge in oral thin films and transdermal patches, driven by consumer preference and resource efficiency. Partnerships between multinational corporations and regional biotech firms are accelerating peptide-based and small molecule innovations, reinforcing the region’s pivotal role in global formulation ecosystems.

Spotlighting Key Company Profiles and Competitive Intelligence to Reveal Strategic Moves Shaping the Future of Drug Formulation and Delivery Innovations

A cohort of leading pharmaceutical and specialty formulation companies is steering the course of the industry. Established organizations such as Pfizer and Roche continue to invest heavily in nanoparticle and liposomal delivery, while Johnson & Johnson and Novartis emphasize controlled-release and targeted peptide platforms. Merck and Sanofi have both broadened their portfolios through strategic acquisitions of biotech firms specializing in vaccine formulation and biologics manufacturing.

Meanwhile, GlaxoSmithKline and AstraZeneca are forging collaborations with contract development and manufacturing organizations to scale inhalation and transdermal solutions. These alliances underscore the growing trend toward outsourcing complex formulations to specialized technology providers. Emerging regional players in Asia-Pacific are also converging on injectable platform innovation, leveraging lower cost structures to introduce high-impact biologics at competitive price points. Collectively, these corporate maneuvers illustrate a dynamic landscape where strategic partnerships and diversified technology investments define competitive advantage.

Formulating Actionable Recommendations for Industry Leaders to Capitalize on Emerging Trends and Strengthen Competitive Advantages in Drug Formulation

To thrive in this rapidly evolving environment, industry leaders should prioritize development of modular manufacturing lines capable of seamlessly transitioning between solid, semisolid, and liquid formats. By cultivating cross-functional teams with expertise in biologics, peptide chemistry, and nanotechnology, organizations can accelerate time to market and reduce technical risk. Moreover, establishing strategic alliances with local suppliers and contract development firms will enhance supply chain resilience in the face of tariff fluctuations and raw material shortages.

Investing in advanced analytical tools and real-world evidence platforms will also prove critical for demonstrating formulation efficacy and patient adherence. Finally, expanding pilot programs for novel delivery routes-such as intranasal sprays and transdermal patches-can yield valuable clinical insights and foster regulatory alignment. Through these targeted actions, companies will be well positioned to capture emerging opportunities, fortify competitive moats, and drive sustainable growth in drug formulation innovation.

Detailing a Rigorous Research Methodology Combining Primary, Secondary, and Data Triangulation Techniques to Ensure Robust Drug Formulation Insights

This analysis is grounded in a rigorous research methodology that integrates primary interviews with C-suite executives, R&D directors, and regulatory experts, complemented by secondary literature reviews of peer-reviewed journal articles and regulatory agency guidelines. Data triangulation techniques were employed to validate findings across multiple sources, ensuring that each insight reflects consensus perspectives and reliable empirical evidence.

Quantitative performance benchmarks were extracted from authenticated manufacturing databases, while case studies provided qualitative depth on formulation successes and challenges. Regional regulatory frameworks were mapped against technical specifications to assess alignment and divergence. This holistic approach ensures that conclusions are not only well supported but also actionable, offering a resilient foundation for strategic decision-making in drug formulation development.

Synthesizing Comprehensive Insights and Strategic Takeaways to Conclude the Executive Summary on Drug Formulation Trends and Opportunities

In conclusion, the drug formulation sector stands at the nexus of scientific innovation, regulatory evolution, and market competitiveness. Key transformative shifts-ranging from the surge in biologics and nanoparticle platforms to the recalibration of supply chains under new tariff regimes-underscore the need for agile strategies. Segment insights reveal that success hinges on aligning therapeutic targets with optimal delivery systems, whether that entails semisolid transdermal gels for neurological indications or controlled-release liposomal injectables for oncology.

Regional analyses highlight how the Americas, Europe, Middle East & Africa, and Asia-Pacific each offer unique opportunities based on manufacturing capabilities, regulatory landscapes, and patient demographics. Company profiles illustrate that strategic partnerships, technology acquisitions, and flexible manufacturing platforms are primary levers for competitive advantage. By synthesizing these findings, industry stakeholders can chart a clear path forward, leveraging robust methodologies and targeted recommendations to drive the next wave of drug formulation breakthroughs.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Area
    • Anti Infectives
    • Cardiovascular
      • Arrhythmia
      • Dyslipidemia
      • Hypertension
    • Central Nervous System
      • Alzheimer’s
      • Depression
      • Parkinson’s
    • Diabetes
    • Gastrointestinal
    • Oncology
      • Breast
      • Colorectal
      • Lung
    • Respiratory
  • Formulation Type
    • Liquid
      • Emulsion
      • Solution
      • Suspension
    • Semi Solid
      • Cream
      • Gel
      • Ointment
    • Solid
      • Capsule
      • Granules
      • Powder
      • Tablet
  • Route Of Administration
    • Inhalation
      • Dry Powder Respirator
      • Metered Dose Inhaler
      • Nebulizer
    • Injectable
      • Intramuscular
      • Intravenous
      • Subcutaneous
    • Nasal
      • Drops
      • Spray
    • Ocular
      • Drops
      • Gel
    • Oral
      • Capsule
      • Powder
      • Tablet
    • Topical
      • Cream
      • Ointment
    • Transdermal
      • Gel
      • Patch
  • Distribution Channel
    • Clinics
    • Drug Stores
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Molecular Type
    • Biologics
    • Peptides
    • Small Molecule
  • Delivery Technology
    • Controlled Release
    • Liposomal
    • Nanoparticle
    • Targeted Delivery
    • Vaccine Formulation
  • Application
    • Human
    • Veterinary
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Catalent, Inc.
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Boehringer Ingelheim International GmbH
  • Siegfried Holding AG
  • Aenova Holding GmbH
  • Piramal Pharma Limited
  • Jubilant Life Sciences Limited
  • Alcami Corporation

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Development of nanoparticle-based targeted drug delivery systems to improve bioavailability in cancer therapy
5.2. Implementation of continuous manufacturing processes for sterile injectable formulations to optimize production efficiency
5.3. Integration of artificial intelligence in formulation design for predictive modeling of drug release profiles
5.4. Adoption of 3D printing technologies for personalized dosage forms in pediatric and geriatric populations
5.5. Formulation strategies for enhancing stability and oral absorption of peptide and protein therapeutics
5.6. Exploration of lipid nanoparticle platforms for mRNA vaccine delivery in pandemic preparedness
5.7. Advances in solvent-free spray drying techniques for environmentally sustainable inhalation therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drug Formulation Market, by Therapeutic Area
8.1. Introduction
8.2. Anti Infectives
8.3. Cardiovascular
8.3.1. Arrhythmia
8.3.2. Dyslipidemia
8.3.3. Hypertension
8.4. Central Nervous System
8.4.1. Alzheimer’s
8.4.2. Depression
8.4.3. Parkinson’s
8.5. Diabetes
8.6. Gastrointestinal
8.7. Oncology
8.7.1. Breast
8.7.2. Colorectal
8.7.3. Lung
8.8. Respiratory
9. Drug Formulation Market, by Formulation Type
9.1. Introduction
9.2. Liquid
9.2.1. Emulsion
9.2.2. Solution
9.2.3. Suspension
9.3. Semi Solid
9.3.1. Cream
9.3.2. Gel
9.3.3. Ointment
9.4. Solid
9.4.1. Capsule
9.4.2. Granules
9.4.3. Powder
9.4.4. Tablet
10. Drug Formulation Market, by Route Of Administration
10.1. Introduction
10.2. Inhalation
10.2.1. Dry Powder Respirator
10.2.2. Metered Dose Inhaler
10.2.3. Nebulizer
10.3. Injectable
10.3.1. Intramuscular
10.3.2. Intravenous
10.3.3. Subcutaneous
10.4. Nasal
10.4.1. Drops
10.4.2. Spray
10.5. Ocular
10.5.1. Drops
10.5.2. Gel
10.6. Oral
10.6.1. Capsule
10.6.2. Powder
10.6.3. Tablet
10.7. Topical
10.7.1. Cream
10.7.2. Ointment
10.8. Transdermal
10.8.1. Gel
10.8.2. Patch
11. Drug Formulation Market, by Distribution Channel
11.1. Introduction
11.2. Clinics
11.3. Drug Stores
11.4. Hospital Pharmacies
11.5. Online Pharmacies
11.6. Retail Pharmacies
12. Drug Formulation Market, by Molecular Type
12.1. Introduction
12.2. Biologics
12.3. Peptides
12.4. Small Molecule
13. Drug Formulation Market, by Delivery Technology
13.1. Introduction
13.2. Controlled Release
13.3. Liposomal
13.4. Nanoparticle
13.5. Targeted Delivery
13.6. Vaccine Formulation
14. Drug Formulation Market, by Application
14.1. Introduction
14.2. Human
14.3. Veterinary
15. Americas Drug Formulation Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Drug Formulation Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Drug Formulation Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Catalent, Inc.
18.3.2. Lonza Group AG
18.3.3. Thermo Fisher Scientific Inc.
18.3.4. Recipharm AB
18.3.5. Boehringer Ingelheim International GmbH
18.3.6. Siegfried Holding AG
18.3.7. Aenova Holding GmbH
18.3.8. Piramal Pharma Limited
18.3.9. Jubilant Life Sciences Limited
18.3.10. Alcami Corporation
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. DRUG FORMULATION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DRUG FORMULATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DRUG FORMULATION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. DRUG FORMULATION MARKET: RESEARCHAI
FIGURE 30. DRUG FORMULATION MARKET: RESEARCHSTATISTICS
FIGURE 31. DRUG FORMULATION MARKET: RESEARCHCONTACTS
FIGURE 32. DRUG FORMULATION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DRUG FORMULATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DRUG FORMULATION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DRUG FORMULATION MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DRUG FORMULATION MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DRUG FORMULATION MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DRUG FORMULATION MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DRUG FORMULATION MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DRUG FORMULATION MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DRUG FORMULATION MARKET SIZE, BY ALZHEIMER’S, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DRUG FORMULATION MARKET SIZE, BY ALZHEIMER’S, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DRUG FORMULATION MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DRUG FORMULATION MARKET SIZE, BY DEPRESSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARKINSON’S, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARKINSON’S, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DRUG FORMULATION MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DRUG FORMULATION MARKET SIZE, BY DIABETES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DRUG FORMULATION MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DRUG FORMULATION MARKET SIZE, BY BREAST, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DRUG FORMULATION MARKET SIZE, BY COLORECTAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DRUG FORMULATION MARKET SIZE, BY COLORECTAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DRUG FORMULATION MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DRUG FORMULATION MARKET SIZE, BY LUNG, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DRUG FORMULATION MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DRUG FORMULATION MARKET SIZE, BY GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL DRUG FORMULATION MARKET SIZE, BY GRANULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL DRUG FORMULATION MARKET SIZE, BY GRANULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER RESPIRATOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER RESPIRATOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL DRUG FORMULATION MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL DRUG FORMULATION MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL DRUG FORMULATION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL DRUG FORMULATION MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL DRUG FORMULATION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL DRUG FORMULATION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL DRUG FORMULATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL DRUG FORMULATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL DRUG FORMULATION MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL DRUG FORMULATION MARKET SIZE, BY NASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL DRUG FORMULATION MARKET SIZE, BY DROPS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL DRUG FORMULATION MARKET SIZE, BY DROPS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL DRUG FORMULATION MARKET SIZE, BY NASAL, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL DRUG FORMULATION MARKET SIZE, BY NASAL, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL DRUG FORMULATION MARKET SIZE, BY OCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL DRUG FORMULATION MARKET SIZE, BY OCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL DRUG FORMULATION MARKET SIZE, BY DROPS, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL DRUG FORMULATION MARKET SIZE, BY DROPS, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL DRUG FORMULATION MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL DRUG FORMULATION MARKET SIZE, BY GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL DRUG FORMULATION MARKET SIZE, BY OCULAR, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL DRUG FORMULATION MARKET SIZE, BY OCULAR, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL DRUG FORMULATION MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL DRUG FORMULATION MARKET SIZE, BY GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL DRUG FORMULATION MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL DRUG FORMULATION MARKET SIZE, BY PATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL DRUG FORMULATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL DRUG FORMULATION MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRUG STORES, BY REGION, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL DRUG FORMULATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL DRUG FORMULATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2025-2030 (USD MILLION)
TABLE 161. GLOBAL DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL DRUG FORMULATION MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 163. GLOBAL DRUG FORMULATION MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL DRUG FORMULATION MARKET SIZE, BY PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 165. GLOBAL DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL DRUG FORMULATION MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 167. GLOBAL DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 169. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 171. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 173. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 174. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOPARTICLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 175. GLOBAL DRUG FORMULATION MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 176. GLOBAL DRUG FORMULATION MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 177. GLOBAL DRUG FORMULATION MARKET SIZE, BY VACCINE FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 178. GLOBAL DRUG FORMULATION MARKET SIZE, BY VACCINE FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 179. GLOBAL DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 180. GLOBAL DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 181. GLOBAL DRUG FORMULATION MARKET SIZE, BY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 182. GLOBAL DRUG FORMULATION MARKET SIZE, BY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 183. GLOBAL DRUG FORMULATION MARKET SIZE, BY VETERINARY, BY REGION, 2018-2024 (USD MILLION)
TABLE 184. GLOBAL DRUG FORMULATION MARKET SIZE, BY VETERINARY, BY REGION, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS DRUG FORMULATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS DRUG FORMULATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS DRUG FORMULATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS DRUG FORMULATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 201. AMERICAS DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. AMERICAS DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 207. AMERICAS DRUG FORMULATION MARKET SIZE, BY NASAL, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS DRUG FORMULATION MARKET SIZE, BY NASAL, 2025-2030 (USD MILLION)
TABLE 209. AMERICAS DRUG FORMULATION MARKET SIZE, BY OCULAR, 2018-2024 (USD MILLION)
TABLE 210. AMERICAS DRUG FORMULATION MARKET SIZE, BY OCULAR, 2025-2030 (USD MILLION)
TABLE 211. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 212. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 213. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 214. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 215. AMERICAS DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, 2018-2024 (USD MILLION)
TABLE 216. AMERICAS DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, 2025-2030 (USD MILLION)
TABLE 217. AMERICAS DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. AMERICAS DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. AMERICAS DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2018-2024 (USD MILLION)
TABLE 220. AMERICAS DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2025-2030 (USD MILLION)
TABLE 221. AMERICAS DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 222. AMERICAS DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 223. AMERICAS DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 224. AMERICAS DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 225. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 226. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES DRUG FORMULATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES DRUG FORMULATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES DRUG FORMULATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES DRUG FORMULATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 247. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 248. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 249. UNITED STATES DRUG FORMULATION MARKET SIZE, BY NASAL, 2018-2024 (USD MILLION)
TABLE 250. UNITED STATES DRUG FORMULATION MARKET SIZE, BY NASAL, 2025-2030 (USD MILLION)
TABLE 251. UNITED STATES DRUG FORMULATION MARKET SIZE, BY OCULAR, 2018-2024 (USD MILLION)
TABLE 252. UNITED STATES DRUG FORMULATION MARKET SIZE, BY OCULAR, 2025-2030 (USD MILLION)
TABLE 253. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 254. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 255. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 256. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 257. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, 2018-2024 (USD MILLION)
TABLE 258. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, 2025-2030 (USD MILLION)
TABLE 259. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. UNITED STATES DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2018-2024 (USD MILLION)
TABLE 262. UNITED STATES DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2025-2030 (USD MILLION)
TABLE 263. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 264. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 265. UNITED STATES DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 266. UNITED STATES DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 267. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 268. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 269. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 270. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 271. CANADA DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 272. CANADA DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 273. CANADA DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
TABLE 274. CANADA DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2030 (USD MILLION)
TABLE 275. CANADA DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 276. CANADA DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 277. CANADA DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 278. CANADA DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 279. CANADA DRUG FORMULATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 280. CANADA DRUG FORMULATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 281. CANADA DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, 2018-2024 (USD MILLION)
TABLE 282. CANADA DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, 2025-2030 (USD MILLION)
TABLE 283. CANADA DRUG FORMULATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 284. CANADA DRUG FORMULATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 285. CANADA DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. CANADA DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 288. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 289. CANADA DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 290. CANADA DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 291. CANADA DRUG FORMULATION MARKET SIZE, BY NASAL, 2018-2024 (USD MILLION)
TABLE 292. CANADA DRUG FORMULATION MARKET SIZE, BY NASAL, 2025-2030 (USD MILLION)
TABLE 293. CANADA DRUG FORMULATION MARKET SIZE, BY OCULAR, 2018-2024 (USD MILLION)
TABLE 294. CANADA DRUG FORMULATION MARKET SIZE, BY OCULAR, 2025-2030 (USD MILLION)
TABLE 295. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 296. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 297. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 298. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 299. CANADA DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, 2018-2024 (USD MILLION)
TABLE 300. CANADA DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, 2025-2030 (USD MILLION)
TABLE 301. CANADA DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. CANADA DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. CANADA DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2018-2024 (USD MILLION)
TABLE 304. CANADA DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2025-2030 (USD MILLION)
TABLE 305. CANADA DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 306. CANADA DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 307. CANADA DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 308. CANADA DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 309. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 310. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 311. MEXICO DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 312. MEXICO DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 313. MEXICO DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
TABLE 314. MEXICO DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2030 (USD MILLION)
TABLE 315. MEXICO DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 316. MEXICO DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 317. MEXICO DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 318. MEXICO DRUG FORMULATION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 319. MEXICO DRUG FORMULATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 320. MEXICO DRUG FORMULATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 321. MEXICO DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, 2018-2024 (USD MILLION)
TABLE 322. MEXICO DRUG FORMULATION MARKET SIZE, BY SEMI SOLID, 2025-2030 (USD MILLION)
TABLE 323. MEXICO DRUG FORMULATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 324. MEXICO DRUG FORMULATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 325. MEXICO DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. MEXICO DRUG FORMULATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
TABLE 328. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION, 2025-2030 (USD MILLION)
TABLE 329. MEXICO DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 330. MEXICO DRUG FORMULATION MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 331. MEXICO DRUG FORMULATION MARKET SIZE, BY NASAL, 2018-2024 (USD MILLION)
TABLE 332. MEXICO DRUG FORMULATION MARKET SIZE, BY NASAL, 2025-2030 (USD MILLION)
TABLE 333. MEXICO DRUG FORMULATION MARKET SIZE, BY OCULAR, 2018-2024 (USD MILLION)
TABLE 334. MEXICO DRUG FORMULATION MARKET SIZE, BY OCULAR, 2025-2030 (USD MILLION)
TABLE 335. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 336. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 337. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 338. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 339. MEXICO DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, 2018-2024 (USD MILLION)
TABLE 340. MEXICO DRUG FORMULATION MARKET SIZE, BY TRANSDERMAL, 2025-2030 (USD MILLION)
TABLE 341. MEXICO DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 342. MEXICO DRUG FORMULATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 343. MEXICO DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2018-2024 (USD MILLION)
TABLE 344. MEXICO DRUG FORMULATION MARKET SIZE, BY MOLECULAR TYPE, 2025-2030 (USD MILLION)
TABLE 345. MEXICO DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 346. MEXICO DRUG FORMULATION MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 347. MEXICO DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 348. MEXICO DRUG FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 349. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 350. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 351. BRAZIL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
TABLE 352. BRAZIL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
TABLE 353. BRAZIL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
TABLE 354. BRAZIL DRUG FORMULATION MARKET SIZE

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Drug Formulation market report include:
  • Catalent, Inc.
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Boehringer Ingelheim International GmbH
  • Siegfried Holding AG
  • Aenova Holding GmbH
  • Piramal Pharma Limited
  • Jubilant Life Sciences Limited
  • Alcami Corporation

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.7 Trillion
Forecasted Market Value ( USD ) by 2030 $ 3.57 Trillion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Drug Formulation Market Report 2025 - Product Image

Drug Formulation Market Report 2025

  • Report
  • 200 Pages
  • Global
From
A Journal of Drug Formulation, Development and Production - Product Image

A Journal of Drug Formulation, Development and Production

  • Journal Icon Journal
  • 60 Pages
  • Global
From
Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Monoclonal Antibody, Insulin, Vaccine, Hormone), By Disease, By Drug Type, By Drug Development Type, By Formulation, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Monoclonal Antibody, Insulin, Vaccine, Hormone), By Disease, By Drug Type, By Drug Development Type, By Formulation, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 225 Pages
  • Global
From
Oral Thin Film Drug Delivery Systems Market - Global Forecast 2025-2030 - Product Image

Oral Thin Film Drug Delivery Systems Market - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From

About the Drug Formulation Market

The Drug Formulation market is a key component of the Drug Discovery process. It involves the development of a drug product that is suitable for administration to a patient. This includes the selection of the appropriate drug delivery system, the optimization of the drug's physical and chemical properties, and the development of a manufacturing process. The formulation of a drug is a complex process that requires expertise in a variety of disciplines, including chemistry, pharmacology, and engineering. The Drug Formulation market is highly competitive, with a number of companies offering a range of services. These include formulation development, analytical testing, and manufacturing. Companies in the market include Pfizer, Merck, Novartis, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.